Voyageur Pharmaceuticals Ltd. (TSXV:VM)
Canada
· Delayed Price · Currency is CAD | Market Cap | 18.84M |
| Revenue (ttm) | 30.96K |
| Net Income (ttm) | -3.34M |
| Shares Out | 179.48M |
| EPS (ttm) | -0.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 28,291 |
| Average Volume | 56,500 |
| Open | 0.110 |
| Previous Close | 0.105 |
| Day's Range | 0.105 - 0.110 |
| 52-Week Range | 0.100 - 0.360 |
| Beta | 0.36 |
| RSI | 40.05 |
| Earnings Date | Apr 14, 2026 |
About Voyageur Pharmaceuticals
Voyageur Pharmaceuticals Ltd., together with its subsidiaries, engages in acquiring, exploring, and developing raw materials for pharmaceutical products in the United States of America, the province of British Columbia, Canada, and the state of Utah. It develops barium and iodine-based APIs. The company offers Smooth HD, Smooth X, Smooth LD, Vision HD, Vision LD, V-Gas, and other products. The company has a collaboration with Bayer Aktiengesellschaft for the research and development of evaluating potential future production of iodine to be used... [Read more]
Financial Performance
Financial StatementsNews
Voyageur Announces Shares for Debt Settlement and Stock Option Repricing
Calgary, Alberta, Canada – TheNewswire - April 17, 2026 – Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (the " Company " or " Voyageur "), a Canadian developer of pharmaceutical-grade barium and iodine fo...
Voyageur Announces Non-Brokered Life Offering
Calgary, Alberta, Canada – March 25, 2026 – TheNewswire - Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (the "Company" or "Voyageur"), a Canadian developer of pharmaceutical-grade barium and iodine for me...
Voyageur Announces Advancements on its Barium & Iodine Contrast Media Projects
Calgary, Alberta, Canada – TheNewswire – March 16, 2026 - Voyageur Pharmaceuticals Ltd . ( TSX-V: VM) (OTC Pink: VYYRF) (the "Company" or "Voyageur"), a pharmaceutical company focused on developing b...
Voyageur Pharmaceuticals Confirms Pharmaceutical-Grade Purity of Barite from Frances Creek and Progresses to Health Canada Human Trial with Alberta Innovates Grant; Announces Stock Option and DSU grants, and Proposed Issuance of Securities for Debt
Purity Exceeding Pharmaceutical Grade, 98.8% BaSO4
Voyageur Pharmaceuticals Announces Collaboration with Bayer
Calgary, Alberta, Canada – TheNewswire – February 23, 2026 - Voyageur Pharmaceuticals Ltd. ( TSXV:VM) ( OTC Pink:VYYRF) (" Voyageur " or the " Company ") a Canadian developer of pharmaceutical-grade ...
Voyageur Pharmaceuticals Strengthens Scientific Team by Adding Dr. Brian Mueller as Director of Chemistry and Secures Exclusive Ownership of Iodine Extraction Technology
Calgary, Alberta, Canada – TheNewswire - January 12, 2026 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC Pink:VYYRF) ("Voyageur" or the "Company"), a Canadian developer of pharmaceutical-grade barium ...
Voyageur Pharmaceuticals Ltd. Strengthens Board of Directors with Seasoned Financial Executive Virginia Alling to Drive U.S. Market Expansion
Calgary, AB – November 7, 2025 – TheNewswire - Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC: VYYRF) (the “Company” or “Voyageur”), a Canadian developer of pharmaceutical-grade barium and iodine for m...
Voyageur Pharmaceuticals Signs Non-Exclusive Distribution & Wholesale Agreement with PHALANX
Calgary, Alberta, Canada – October 29, 2025 – TheNewswire - Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) (“Voyageur” or the “Company”), a Canadian public company developing cost-effective...
Voyageur Clarifies Terms of Previously Announced Agreement
Calgary, Alberta--(Newsfile Corp. - March 3, 2025) - Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC Pink: VYYRF) ("Voyageur" or the "Company") wishes to clarify the terms of a distribution and wholesal...
Voyageur Receives $600K Grant from Alberta Innovates for Product Development
Voyageur receives $600,000 in funding through Alberta Innovates AICE-Market Access Program
Voyageur Announces Proposed Private Placement
Calgary, Alberta--(Newsfile Corp. - October 17, 2024) - Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC Pink: VYYRF) ("Voyageur" or the "Corporation"), is pleased to announce a proposed non-brokered pri...
Voyageur Pharmaceuticals Grants Stock Options
Calgary, Alberta--(Newsfile Corp. - September 25, 2024) - Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC Pink: VYYRF) ("Voyageur" or the "Company") announces that it has granted an aggregate of 600,000...
Voyageur Pharmaceuticals Ltd. Announces Equity Incentive Compensation
Calgary, Alberta--(Newsfile Corp. - December 2, 2022) - Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC Pink: VYYRF) (the "Company" or "Voyageur") announces that it has issued 125,322 Deferred Share Uni...
Voyageur Pharmaceuticals Ltd. Issuance of 5th Product License for MultiXThick Radiographic Barium Contrast
Voyageur Pharmaceuticals is moving forward with FDA device registrations for the US market. Voyageur Pharmaceuticals is moving forward with FDA device registrations for the US market.
Voyageur Pharmaceuticals Ltd. Issued 4th Health Canada License For Radiographic Barium Contrast Product
Voyageur is moving forward with its business plan of becoming the only fully-integrated company in the radiographic contrast medical field Voyageur is moving forward with its business plan of becoming...